table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
bamlanivimab monotherapy ACTIV-3/TICO LY-CoV555

3 studies excluded by filtering options 0

6920 Rainwater-Lovett, 2021 0130selection pending
6921 Bariola, 2021 1130not a RCTrisk of bias not avaialble
9265 OPTIMISE-C19 (bamlanivimab monotherapy vs casirivimab-imdevimab), 2021 010selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons